Chiusura precedente | 117,13 |
Aperto | 116,22 |
Denaro | 112,73 x 800 |
Lettera | 113,00 x 1100 |
Min-Max giorno | 112,90 - 117,52 |
Intervallo di 52 settimane | 89,00 - 238,55 |
Volume | |
Media Volume | 2.473.606 |
Capitalizzazione | 17,935B |
Beta (5 anni mensile) | 1,09 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -7,10 |
Prossima data utili | 05 feb 2024 - 09 feb 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 131,50 |
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous rec